How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/metastatic-urothelial-carcinoma.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Metastatic urothelial carcinoma — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Metastatic urothelial carcinoma (disease) competitive landscape: 5 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

5 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Metastatic urothelial carcinoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Padcev	AGS-22M6E	Astellas Pharma		Nectin-4	2019-01-01
Enfortumab	padcev	Astellas Pharma		Nectin-4	2019-01-01
Balversa	ERDAFITINIB	Johnson & Johnson	Kinase Inhibitor [EPC]	Fibroblast growth factor receptor 1	2019-01-01
Enfortumab	Enfortumab	Brigham and Women's Hospital		Nectin-4, Tubulin beta
Balversa	Balversa	xCures		Fibroblast growth factor receptor 1, Fibroblast growth factor receptor 2, Fibroblast growth factor receptor 3

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Astellas Pharma · 2 drugs in Metastatic urothelial carcinoma
Brigham and Women's Hospital · 1 drug in Metastatic urothelial carcinoma
Johnson & Johnson · 1 drug in Metastatic urothelial carcinoma
xCures · 1 drug in Metastatic urothelial carcinoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Metastatic urothelial carcinoma:

Cite this brief

Drug Landscape (2026). Metastatic urothelial carcinoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/metastatic-urothelial-carcinoma. Accessed 2026-06-10.

Metastatic urothelial carcinoma full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing